Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Full description

Bibliographic Details
Published in:	Blood Advances
Main Authors:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Article
Language:	English
Published:	Elsevier 2017-06-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952920302056

Similar Items

Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946.
Published: (2017-08-01)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
by: Caroline Dartigeas, et al.
Published: (2022-09-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
by: Xue Yi, et al.
Published: (2022-02-01)

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
by: Alexandria P. Eiken, et al.
Published: (2024-08-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
by: Steven Le Gouill, et al.
Published: (2023-08-01)

P107 | CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE REAL WORD :THE CAMPANIA EXPERIENCE WITH FIRST –LINE IBRUTINIB AND VENETOCLAX
by: G. Farina, et al.
Published: (2025-09-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
by: Carsten U. Niemann, et al.
Published: (2025-08-01)

S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL
by: I. Solman, et al.
Published: (2022-06-01)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
by: Christoph Kornauth, et al.
Published: (2021-02-01)

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells
by: Fengbo Jin, et al.
Published: (2024-10-01)

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient
by: Kim Abbegail Tan Aldecoa, et al.
Published: (2023-01-01)

REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
by: V Pfister, et al.
Published: (2024-10-01)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment
by: Stephanie Herold, et al.
Published: (2025-08-01)

The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL
by: Joaquín Marco-Brualla, et al.
Published: (2025-08-01)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
by: Lydia Scarfò, et al.
Published: (2023-08-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
by: Arnon Kater, et al.
Published: (2023-08-01)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
by: P. Hillmen, et al.
Published: (2022-06-01)

P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
by: L. J. Croner, et al.
Published: (2022-06-01)

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
by: Sabah Kadri, et al.
Published: (2017-05-01)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
by: Gianluigi Reda, et al.
Published: (2018-06-01)

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
by: Brian J Capaldo, et al.
Published: (2015-01-01)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
by: Jacopo Olivieri, et al.
Published: (2022-06-01)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
by: Rocio Figueroa, et al.
Published: (2020-11-01)

Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials
by: Ahmad Y. Abuhelwa, et al.
Published: (2025-07-01)

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01)

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
by: Chaitra Ujjani, et al.
Published: (2018-04-01)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
by: Melissa A. Fischer, et al.
Published: (2022-08-01)

A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation
by: Alexander F. vom Stein, et al.
Published: (2025-05-01)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: J. C. Barrientos, et al.
Published: (2022-06-01)

Paraneoplastic myelitis associated with Waldenström macroglobulinemia responsive to treatment with ibrutinib – venetoclax: A case report
by: Sathya Narasimhan, et al.
Published: (2024-12-01)

P440: THE COMBINATION VENETOCLAX PLUS MCL1 OVERCOMES DRUG RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA
by: D. A. Pereira-Martins, et al.
Published: (2022-06-01)